CervoMed (CRVO) had its "buy" rating reaffirmed by Chardan Capital. They now have a $15.00 price target on the stock.
CervoMed to Participate in Upcoming Investor Conferences
CervoMed (CRVO) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $31.00 price target on the stock.
CervoMed Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy Bodies
CervoMed (NASDAQ:CRVO) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $31.00 price target on the stock.